As REPROCELL emerges from the first quarter of 2023-24, we are thrilled to present a snapshot of the activities and achievements that have set the stage for a productive year. From the launch of our new Pharmacology-AI service to winning a grant for the generation of NK cells from iPSCs, we have demonstrated our commitment to innovation, growth, and global impact. Join us as we list the highlights of REPROCELL's dynamic quarter below:
- Things to consider when searching for a supplier of cGMP iPSCs [WEBINAR]
- Pharmacology-AI: Machine learning for precision medicine, made easy [EXPLAINER VIDEO]
- Wire myography: the ultimate guide [protocol included] [BLOG POST]
- Why do patients respond differently to drugs? AI may provide an answer [BLOG POST]
- REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapy Medicinal Products [PRESS RELEASE]
- Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia [PRESS RELEASE]
- Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform [PRESS RELEASE]
- Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer [PRESS RELEASE]
As always - if you have any questions about our products and service, please do not hesitate to get in touch.
